sustained reductions
-
Pharma
Nipocalimab cuts lupus disease activity in Phase 2 trial
Late-breaking data presented at EULAR 2026 showed sustained reductions in systemic lupus erythematosus disease activity through 52 weeks, with the…
Read More »